Antibiofilm Drug Discovery

Antibiofilm drug discovery is necessary for developing new drugs, biocides and wound management protocols. This makes the standardization and implementation of in vitro antibiofilm screening platforms a challenge in the search for new antibiotics, because current antimicrobials are active against planktonic bacteria and have poor diffusion across biofilm matrix. Usually, based in the research topic, the antibiofilm methods have been classified in static and flow depending of continuous supply of nutrients that affect the microbial growth, the final aim of these assays is obtain Minimal Biofilm Inhibitory Concentration (MBIC) and Minimal Biofilm Eradication Concentration (MBEC) values as efficacy parameter of the compound or procedure evaluated, but is very important correlates data from different models in order to give real results of activity. OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals. Journal of Bacteriology & Parasitology is one of the top Peer-reviewed open access journals that emphasises Microbiological, diagnosis, treatment of infections with their Therapeutic & diagnostics aspects. It publishes original research articles, novel, and scientifically sound findings dealing with Bacteria and Parasites of Medical relevance to human or veterinary health, as well as those with application in Environmental or Food Sciences related to microbiology.

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on September, 2024